Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT06099886
PHASE1
Repurposing Lithium for Parkinson's Disease
Sponsor: State University of New York at Buffalo
View on ClinicalTrials.gov
Summary
This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.
Official title: Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: A Phase I Trial
Key Details
Gender
All
Age Range
45 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2023-10-12
Completion Date
2025-04-30
Last Updated
2026-04-14
Healthy Volunteers
No
Conditions
Interventions
DIETARY_SUPPLEMENT
Lithium aspartate
Lithium aspartate 30-45mg/day
Locations (1)
University at Buffalo
Williamsville, New York, United States